For the first time since the COVID-19 pandemic, the annual number of lung transplants performed in the United States increased. The year 2022, encompassed in this report, marks the last full calendar year where the Lung Allocation Score was used for ranking transplant candidates based on their estimated transplant benefit and donor lung allocation in the United States. In March 2023, a major change in transplant allocation policy occurred with the implementation of the Composite Allocation Score. Transplant rates have increased over the past decade, although there is variability among age, diagnosis, racial and ethnic, and blood groups. Over half of candidates received a lung transplant within 3 months of placement on the waiting list, with nearly 75% of candidates accessing transplant by 1 year. Pretransplant mortality rates remained stable, with approximately 13% of lung transplant candidates dying or being removed from the waiting list within a year of listing. Posttransplant survival remained stable; however, variability exists by age, diagnosis, and racial and ethnic groups.

中文翻译：

---

OPTN/SRTR 2022 年度数据报告：肺

自 COVID-19 大流行以来，美国每年进行的肺移植手术数量首次增加。本报告所涵盖的 2022 年是最后一个完整日历年，其中肺分配评分用于根据美国的估计移植效益和供体肺分配对移植候选者进行排名。 2023年3月，随着综合分配评分的实施，移植分配政策发生重大变化。尽管年龄、诊断、种族和民族以及血型之间存在差异，但移植率在过去十年中有所增加。超过一半的候选人在进入等候名单后 3 个月内接受了肺移植，近 75% 的候选人在 1 年后接受了肺移植。移植前死亡率保持稳定，大约 13% 的肺移植候选者在上市后一年内死亡或从等待名单中删除。移植后存活率保持稳定；然而，年龄、诊断以及种族和族裔群体之间存在差异。